A possible role for thrombopoietin and its receptor c-mpl in the pathobiology of essential thrombocythemia

Seminars in Thrombosis and Hemostasis

Volumn 23, Issue 5, 1997, Pages 419-423

  Griesshammer, Martin ^a,b   Bangerter, Markus ^a   Schrezenmeier, Hubert ^a  

^a UNIVERSITY OF ULM   (Germany)

^b Department of Internal Medicine III ^*  (Germany)

Author keywords

c mpl receptor; Essential thrombocythemia; Pathobiology; Thrombopoietin

Indexed keywords

ONCOPROTEIN; THROMBOPOIETIN;

ARTICLE; FEEDBACK SYSTEM; GENE OVEREXPRESSION; HUMAN; MEGAKARYOCYTE; MEGAKARYOPOIESIS; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTO ONCOGENE; THROMBOCYTE; THROMBOCYTHEMIA;

EID: 0030774053     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996118     Document Type: Article

References (33)

1. Yan L, N Elkassar, C Gardin, et al: Clonality assays and megakaryocyte culture techniques in essential thrombocythemia. Leukemia Lymphoma 22 (suppl 1):31-40, 1996.
2. Kaushansky K: Thrombopoietin: The primary regulator of platelet production. Blood 86:419-431, 1995.
3. De Sauvage FJ, DL Eaton: Thrombopoietin: The primary regulator of megakaryocytopoiesis and thrombopoiesis. Exp Hematol 25:1-7, 1997.
4. Kaushansky K: Thrombopoietin: In vitro predictions, in vivo realities. Am J Hematol 53:188-191, 1996.
5. Wendung F, P Varlet, M Charon, et al: A retrovirus complex inducing an acute myeloproliferative leukemia disorder in mice. Virology 149:242-246, 1986.
6. Souyri M, I Vigon, JF Penciolelli, et al: A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 63:1137-1147, 1990.
7. Vigon I, JP Mornon, L Cocault, et al: Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: Identification of a member of the hematopoietic growth factor receptor superfamily. Proc Natl Acad Sci USA 89:5640-5644, 1992.
8. Kaushansky K, S Lok, RD Holly, et al: Promotion of megakaryocyte progenitor expansion and differentiation by the c-mpl ligand thrombopoietin. Nature 369:568-571, 1994.
9. Broudy VC, NL Lin, K Kaushansky: Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and IL-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 85: 1719-1726, 1995.
10. Farese AM, P Hunt, T Boone, et al: Recombinant human megakaryocyte growth and development factor stimulates thrombocytosis in normal nonhuman primates. Blood 86:54-59, 1995.
11. Basser R, K Clarke, R Fox, et al: Randomized, douhle-blind, placebo-controlled phase I trial of pegylated megakaryocyte growth and development factor (PEG-rHuMGDF) administered to patients with advanced cancer before and after chemotherapy. Blood 86 (suppl 10):257(Abstr 1014), 1995.
12. Gurney AL, K Carver-Moore, FJ de Sauvage, et al: Thrombocytopenia in c-mpl-deficient mice. Science 265:1445-1447, 1994.
13. De Sauvage KJ, SM Luoh, K Carver-Moore, et al: Deficiencies in early and late stages of megakaryocytopoiesis in TPO-KO mice. Blood 86 (suppl 10):255 (Abstr 1007), 1995.
14. Kuter DJ, RD Rosenberg: The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 85:2720-2730, 1995.
15. Fielder PJ, AL Gurney, E Stefanich, et al: Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 87:2154-2161, 1996.
16. Villeval JL, K Cohen-Solal, M Tulliez, et al: Dysregulated thrombopoietin (TPO) production induces a fatal myeloproliferative syndrome in mice. Exp Hematol 24:1071(Abstr 255), 1996.
17. Yan XO, D Lacey, D Hill, et al: A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): Reversal of disease by bone marrow transplantation. Blood 88:402-409, 1996.
18. Wang JC, C Chen, L Loui, et al: Blood thrombopoietin (TPO) levels in patients with agnogenic myeloid metaplasia (AMM). Blood 88(suppl 1):212(Abstr 3575), 1996.
19. Emmons RVB, DM Reid, RL Cohen, et al: Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood 87:4068-4071, 1996.
20. Meng YG, TG Martin, ML Peterson, et al: Circulating thrombopoietin concentrations in thrombocytopenic patients, including cancer patients following chemotherapy, with or without peripheral blood progenitor cell transplantation. Br J Haematol 95:535-541, 1996.
21. Schrezenmeier H, M Griesshammer, A Hornkohl, et al: Endogenous thrombopoietin (TPO) levels in serum of patients with aplastic anemia (AA). Ann Haematol 73(suppl II):174(Abstr 695), 1996.
22. Marsh CW, M Gibson, RL Prue, et al: Serum thrombopoietin levels in patients with aplastic anaemia. Br J Haematol 95: 605-610, 1996.
23. Kunishima S, T Tahara, T Kato, et al: Serum thrombopoietin and plasma glycocalicin concentrations as useful diagnostic markers in thrombocytopenic disorders. Eur J Haematol 57:68-71, 1996.
24. Usuki K, T Tahara, S Iki, et al: Serum thrombopoietin level in various hematological diseases. Stem Cells 14:558-565, 1996.
25. Tahara T, K Usuki, H Sato, et al: A sensitive sandwich ELISA for measuring thrombopoietin in human serum: Serum thrombopoietin levels in healthy volunteers and in patients with haemopoietic disorders. Br J Haematol 93:783-788, 1996.
26. Taylor K, L Pitcher, J Nichol, et al: Inappropriate elevation and loss of feedback regulation of thrombopoietin in essential thrombocythaemia (ET). Blood 86(suppl 1):49(Abstr 183), 1995.
27. Griesshammer M, A Hornkohl, JL Nichol, et al: Elevated endogenous thrombopoietin (TPO) levels in sera of patients with essential thrombocythemia (ET): Cause or consequence of abnormal platelet production? Ann Hematol 73(suppl II):97(Abstr 385), 1996.
28. Wang JC, C Chen, J Nichol: Serum thrombopoietin (TPO) levels in patients with essential thrombocytosis (ET) and reactive thrombocytosis (RT). Blood 88(suppl 1):212(Abstr 3576), 1996.
29. Li Y, G Hetet, JJ Kiladjian, et al: Proto-oncogene c-mpl is involved in spontaneous megakaryocytopoiesis in myeloproliferative disorders. Br J Haematol 92:60-66, 1996.
30. Martin JM, YK Gandhi, WR Jackson, et al: Hypersensitivity of polycythemia vera megakaryocytic progenitors to thrombopoietin. Blood 88(suppl 1): 94(Abstr 363), 1996.
31. Debili N, JP Le Couedic, C Ternisien, et al: Autonomous growth of megakaryocyte progenitors in essential thrombocythemia is not due to a mutation of c-mpl. Blood 88(suppl 1): 98(Abstr 379), 1996.
32. Taylor K, D Taylor, P Favot, et al: Failure to show molecular evidence for involvement of thromhopoietin (TPO) and c-mpl genes in essential thrombocythemia (ET). Blood 88(suppl 1): 210(Abstr 3573), 1996.
33. Li J, Y Xia, DJ Kuter: Analysis of the thrombopoietin receptor (mpl) on platelets from normal and essential thrombocythemic (ET) patients. Blood 88(suppl 1):595(Abstr 2168), 1996.